Chuck Stevens is the chief executive officer of COPILOT. He leverages almost three decades of bio-pharmaceutical industry experience to lead the executive team and drive the company’s transformational HUB strategies. Before being named CEO in 2023, he served as COPILOT’s chief operating officer, where he developed strategic operations plans to support revenue and market share and was responsible for strategic reimbursement, pricing, payer strategy, product distribution, medical communications, payer marketing, and HEOR modeling.

Chuck specializes in hematology, oncology, infectious diseases, addiction medicine, CNS, OA, and rare disorder products. Before joining COPILOT, Chuck served as the president of MediMedia/CHC and head of global access and commercialization at ICON and led a team of over 400 life science consultants. Prior to this, he was the vice president and general manager of PAREXEL’s reimbursement HUB, health policy, and market access consulting practice. In the past, Chuck also held commercial positions at Cephalon Oncology, Cell Therapeutics, Genetics Institute (Wyeth Oncology), and Abbott Laboratories.

Chuck is a former Captain in the United States Army and a veteran of Operation Desert Storm. He graduated from Northeastern University with a Bachelor of Science degree in Business Administration. He has an MBA from Clark University, a Juris Doctor Degree from Suffolk University Law School, and attended the Massachusetts Senior Executive Program at Harvard University’s John F. Kennedy School of Government. Chuck is a member of the Bar of the Supreme Court of the United States and of the Commonwealth of Massachusetts.